This paper is in the following e-collection/theme issue:

RCTs - Protocols/Proposals (eHealth) (538)

Published on in Vol 7, No 8 (2018): August

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/10516, first published .
The Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial

The Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial

The Use of Aspirin to Reduce the Risk of Thrombotic Events in Patients With End-Stage Renal Disease: Protocol for a Randomized Controlled Trial

Authors of this article:

Tiago Lemos Cerqueira1, 2, 3 Author Orcid Image ;   Armando Fartolino Guerrero2, 4 Author Orcid Image ;   Clara Krystal Pérez Fermin2, 5 Author Orcid Image ;   Ricardo Wang2, 6 Author Orcid Image ;   Evelin Elfriede Balbino2, 7 Author Orcid Image ;   Janis L Breeze8, 9 Author Orcid Image ;   Paola Gonzalez Mego2, 10 Author Orcid Image ;   Daniele Argentina Silva2, 11 Author Orcid Image ;   Walid Ezzeldin Omer2, 12 Author Orcid Image ;   Nathalie Monique Vandevelde2, 13 Author Orcid Image
Article Authors Cited by (2) Tweetations (9) Metrics

Journals

  1. Goel N, Jain D, Haddad D, Shanbhogue D. Anticoagulation in Patients with End-Stage Renal Disease and Atrial Fibrillation: Confusion, Concerns and Consequences. Journal of Stroke 2020;22(3):306 View
  2. Natale P, Palmer S, Saglimbene V, Ruospo M, Razavian M, Craig J, Jardine M, Webster A, Strippoli G. Antiplatelet agents for chronic kidney disease. Cochrane Database of Systematic Reviews 2022;2022(2) View